In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapyon December 8, 2019 at 9:02 am
“Current patient- and donor-specific CAR T-cell immunotherapies recognize only one antigen and fail ... Ph.D., Chief Development Officer of Fate Therapeutics. “Additionally, since FT596 is ...
- Does Shield Therapeutics plc (LON:STX) Have A Particularly Volatile Share Price?on December 6, 2019 at 4:14 pm
Anyone researching Shield Therapeutics plc (LON:STX) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there ...
- Melanoma Therapeutics Market Expert Reviews & Analysis 2019 Along With Study Reportson December 6, 2019 at 5:00 am
Dec 06, 2019 (Market Insight Reports via COMTEX) -- Global Melanoma Therapeutics Market 2019:This report tracks the major market events including development trends, mergers & acquisitions and the ...
- TG Therapeutics Recaps Schedule of Triple Therapy Data Presentations at the Upcoming 61st American Society of Hematology Annual Meeting and Expositionon December 6, 2019 at 3:30 am
Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing ...
- Autolus Therapeutics: Intriguing Oncology Name From Across The Pondon December 5, 2019 at 9:41 am
Autolus Therapeutics plc (NASDAQ:AUTL) is a London-based ... Autolus is leveraging its expertise in T cells to not only reprogram them to overcome those defense mechanisms and attack a specific cancer ...
- Pioneering the Discovery and Development of Novel Therapeutics to Prevent Metastasison December 4, 2019 at 10:54 am
Eventually, these dormant DTCs “awaken” in response to specific cues from their surrounding microenvironment ... When it comes to our therapeutic portfolio, we believe that targeting these signature ...
- SPR Therapeutics Announces 1000th Sprint PNS Procedureon December 4, 2019 at 5:38 am
The MicroLead delivers mild electrical pulses targeted to a specific peripheral nerve. CLEVELAND, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for ...
- Drops containing a specific probiotic strain can reduce colic in infantson December 4, 2019 at 12:44 am
In a new trial published in the journal Alimentary Pharmacology & Therapeutics, investigators have shown that ... "It is relevant to underline that this trial studied a specific well-characterized ...
- MicroRNA Tools, Diagnostics and Therapeutics: Global Analysis, Opportunities and Forecast To 2024on December 3, 2019 at 11:50 pm
researchers have reported several findings on specific microRNAs. The collaborative efforts of researchers and pharmaceutical industry are establishing miRNA as promising future drug candidate.
- Microbiome Therapeutics Market Growth, Indepth Insight And Research Finding To 2019-2029on December 3, 2019 at 11:44 pm
Research Methodology and Conclusion: In this section specific procedures or techniques used to identify, select, process, and analyze information about a Microbiome Therapeutics market is included.
via Bing News